Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on ...

In celebration of Ophthalmology Times 50th anniversary, we asked leading experts in the field what they see as the biggest ...

The trial is designed to assess the safety and effectiveness of Avisi Technologies' investigational VisiPlate device in ...

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...

Multiple myeloma is a rare cancer that originates in white blood cells (plasma cells) that produce antibodies.

Andrew G. Lee, MD, and Drew Carey, MD, return for this episode of 'NeuroOp Guru' to discuss how sixth nerve palsy with ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The approval makes ILM-Blue the first DORC posterior dye product available in China, according to a press release from Zeiss.

The May 4 event, themed around Star Wars, will feature the latest innovations, foster open discussions, and provide a ...

Urcosimod (formerly known as OK-101) has been shown to be stable for over 2 and a half years in single-use ampoules used for ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.